Urge Servier to continue Sevasemten trials

862

Let’s get to 1000 signatures!
Petitions with 1,000+ supporters are 5x more likely to win!

The Issue

We are advocating for all those with Becker and its closely related disease, Duchenne Muscular Dystrophy.  The abrupt end to the drug development of Sevasemten  - ends our hope for the first treatment to fight this disease in our lifetime. We live with the difficult realities of these progressive, muscle-deteriorating diseases every day. Becker and Duchenne muscular dystrophy affect more than skeletal muscles; it impacts the heart and lungs,  shortening life expectancy and robbing these boys and men of things we take for granted like climbing stairs, running and eventually the ability to walk or even sit comfortably. But hope had a name—Sevasemten, the promising drug aimed at improving the quality and length of life for those with Becker and Duchenne Muscular Dystrophy. Initially developed by Edgewise Therapeutics, the development of this drug was recently sold in July 2026 to Servier Pharmaceuticals (part of Servier Group, a French pharmaceutical company) for $1.55 billion in upfront cash (with milestone payment considerations up to $1.1 billion more). This week Servier announced full program termination and will stop all development and trials of this promising drug. Stopping development has nothing to do with safety as Servier found it to be safe and well tolerated. Unfortunately, this premature decision is to the extreme detriment of those on the drug (seeing life changing positive results) as well as those hoping for future access to the drug.

Sevasemten reached Phase 3 in its clinical trials, the critical juncture where a drug is often deemed safe and effective before heading to FDA submission for approval. This drug was deemed very safe and well tolerated in all prior trials with the worst side effects being dizziness, headache or fatigue. This drug also held steady or slightly improved functional tests in Phase 2b trials for patients - how far they could walk in 6 minutes or the stair climb test when typically these would decrease rapidly through natural disease progression.

As of today, there are no cures for either Becker or Duchenne Muscular Dystrophy. Treatments are limited, mostly focused on managing symptoms and Becker has ZERO approved treatments. But Sevasemten represented a beacon of hope. It showed the promise of slowing progression of these horrible diseases—an essential shift in the treatment paradigm. 

The stakes couldn't be higher. Men and boys in these drug trials over the last four years have reported remarkable improvements in their daily function. This cessation of development seems premature and is devastating to families, who cling to every thread of hope for a better future. It is most sad for the patients who have been on the drug and see improved results. Having this lifeline ripped out from underneath them is horrible. At a minimum these patients should be allowed to continue this drug for compassionate care. 

Five drugs to treat Duchenne muscular dystrophy that were developed by other companies ALL failed their primary endpoints, but they ALL pivoted to other approval options or subsets of the data and received APPROVAL. Why is Servier giving up without trying any options other drug companies successfully pursued with arguably drugs with worse safety profiles? A 2023 study published in JAMA Internal Medicine estimated that 10% of the approved drugs in the market failed their phase 3 primary endpoints. A failed trial is NOT a failed drug and one setback is not reason to cancel it all.

Our call is simple yet urgent: We urge Servier to find a feasible solution to continue the Sevasemten trials toward FDA submission for approval. Keep these trials alive through creative collaboration, alternative funding strategies, or partnerships with organizations equally committed to the cause. We ask Servier to remember that behind every number is a family in need of more time, more hope, and a better life. Purchasing this drug development from Edgewise to kill it 4 months later is unethical - give this more time.

Please join me in urging Servier to act decisively and compassionately. Lend your voice to ensure that Sevasemten can continue its critical path toward becoming the breakthrough drug we are waiting for. Sign this petition to ensure that hope does not fade away for those living with Becker and Duchenne Muscular Dystrophy.

Supporter Voices

Petition Updates